trending Market Intelligence /marketintelligence/en/news-insights/trending/ohA1DN7nZ5ABr2plBqFLlg2 content esgSubNav
In This List

Avadel's injection for neonatal nutrition approved by US FDA

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Avadel's injection for neonatal nutrition approved by US FDA

Avadel Pharmaceuticals PLC's Nouress, an injection that provides nutrition to neonatal patients, has been approved by the U.S. Food and Drug Administration.

Nouress is a cysteine hydrochloride injection for neonatal patients that require total parenteral nutrition, a feeding system that delivers liquid nutrients like carbohydrates, proteins and fats intravenously, according to the Mayo Clinic.

Dublin-based Avadel, a pharmaceutical company focused on treating narcolepsy, also said in a Dec. 16 press release that the U.S. Patent and Trademark Office has issued a patent covering the Nouress product. The patent is set to expire in March 2039. The company has other U.S. patent applications pending for Nouress.

Avadel said the U.S. launch date for Nouress is still being decided. A similar product manufactured by Exela Pharma Sciences LLC called ELCYS was approved by the FDA in May, with an immediate launch.

Shares of Avadel were down 12.22% to $6.32 as of 12:07 p.m. ET on Dec. 16.